Movement Alert｜Twist Bioscience Corp Rises 5.65% in Pre-Market Trading, Strong Q4 Revenue Guidance Fuels Technical Rebound After Sharp Selloff

Market Focus08-19 19:38

On August 19, Twist Bioscience Corp rose 5.65% in pre-market trading to $122.66/share, with turnover of $1.5723 million. The stock closed the prior session down 6.68% at $116.10, and the pre-market move represents a notable recovery.

The rebound is supported by the company's fiscal Q3 earnings released on August 3, which showed revenue of $118.4 million, beating the consensus estimate of $114.5 million. More importantly, management issued Q4 revenue guidance of $123 million to $124 million, significantly above the FactSet estimate of $117.4 million. As a core DNA synthesis supplier within the AI-driven drug discovery value chain, the company's protein solutions business has demonstrated strong growth momentum. The recent completion of a $300 million equity offering to expand production capacity further reinforces the improving fundamental outlook, providing a catalyst for a technical bounce following the prior session's steep decline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181067556?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-19 19:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181067556","market":"us","top_or_hot":-1,"title":"Movement Alert｜Twist Bioscience Corp Rises 5.65% in Pre-Market Trading, Strong Q4 Revenue Guidance Fuels Technical Rebound After Sharp Selloff","media":"Market Focus","content":"<p><p>On August 19, Twist Bioscience Corp rose 5.65% in pre-market trading to $122.66/share, with turnover of $1.5723 million. The stock closed the prior session down 6.68% at $116.10, and the pre-market move represents a notable recovery.</p><p>The rebound is supported by the company's fiscal Q3 earnings released on August 3, which showed revenue of $118.4 million, beating the consensus estimate of $114.5 million. More importantly, management issued Q4 revenue guidance of $123 million to $124 million, significantly above the FactSet estimate of $117.4 million. As a core DNA synthesis supplier within the AI-driven drug discovery value chain, the company's protein solutions business has demonstrated strong growth momentum. The recent completion of a $300 million equity offering to expand production capacity further reinforces the improving fundamental outlook, providing a catalyst for a technical bounce following the prior session's steep decline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Twist Bioscience Corp Rises 5.65% in Pre-Market Trading, Strong Q4 Revenue Guidance Fuels Technical Rebound After Sharp Selloff</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Twist Bioscience Corp Rises 5.65% in Pre-Market Trading, Strong Q4 Revenue Guidance Fuels Technical Rebound After Sharp Selloff\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-19 19:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 19, Twist Bioscience Corp rose 5.65% in pre-market trading to $122.66/share, with turnover of $1.5723 million. The stock closed the prior session down 6.68% at $116.10, and the pre-market move represents a notable recovery.</p><p>The rebound is supported by the company's fiscal Q3 earnings released on August 3, which showed revenue of $118.4 million, beating the consensus estimate of $114.5 million. More importantly, management issued Q4 revenue guidance of $123 million to $124 million, significantly above the FactSet estimate of $117.4 million. As a core DNA synthesis supplier within the AI-driven drug discovery value chain, the company's protein solutions business has demonstrated strong growth momentum. The recent completion of a $300 million equity offering to expand production capacity further reinforces the improving fundamental outlook, providing a catalyst for a technical bounce following the prior session's steep decline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TWST","symbol_name":"Twist Bioscience Corp","start_time":0,"source_url":"","article_id":"1181067556","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181067556","pubTimestamp":1787139488,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 19, Twist Bioscience Corp rose 5.65% in pre-market trading to $122.66/share, with turnover of $1.5723 million. The stock closed the prior session down 6.68% at $116.10, and the pre-market...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TWST":"Twist Bioscience Corp"},"translate_title":"走势警报|Twist Bioscience Corp 盘前交易中上涨 5.65%，强劲的第四季度收入指引推动大幅抛售后技术反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TWST":1},"content_text":"On August 19, Twist Bioscience Corp rose 5.65% in pre-market trading to $122.66/share, with turnover of $1.5723 million. The stock closed the prior session down 6.68% at $116.10, and the pre-market move represents a notable recovery.The rebound is supported by the company's fiscal Q3 earnings released on August 3, which showed revenue of $118.4 million, beating the consensus estimate of $114.5 million. More importantly, management issued Q4 revenue guidance of $123 million to $124 million, significantly above the FactSet estimate of $117.4 million. As a core DNA synthesis supplier within the AI-driven drug discovery value chain, the company's protein solutions business has demonstrated strong growth momentum. The recent completion of a $300 million equity offering to expand production capacity further reinforces the improving fundamental outlook, providing a catalyst for a technical bounce following the prior session's steep decline.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181067556","isCrawlerRequest":true}